# US 2013/0260392 A1 · Tagged ligands for enrichment of rare analytes from a mixed sample

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0260392 A1
- Document ID: US20130260392A1
- Status: Published application
- Kind: A1
- Application number: 13/692,710
- Filed: 2012-12-03
- Published: 2013-10-03
- Earliest claimed: 2008-02-25
- Assignees: On-Q-ity
- Applicants: On-Q-Ity, Inc.
- Inventors: Allyn Forsyth; Helen Barnes
- Web page: https://patentgrep.com/patent/US20130260392A1

## CPC

- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- B01L 3/502761: {specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads or physically stretching molecules}
- G01N 1/405: {by adsorption or absorption}
- G01N 33/54326: {Magnetic particles}
- G01N 33/575: for cancer
- G01N 33/585: {with a particulate label, e.g. coloured latex}
- B01L 2200/0647: Handling flowable solids, e.g. microscopic beads, cells, particles
- B01L 2300/0861: Configuration of multiple channels and/or chambers in a single devices
- B01L 2400/086: using baffles or other fixed flow obstructions
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- Y10S 435/971: Capture of complex after antigen-antibody reaction
- Y10S 435/973: Simultaneous determination of more than one analyte
- Y10T 436/101666: Particle count or volume standard or control [e.g., platelet count standards, etc.]
- Y10T 436/13: Tracers or tags
- Y10T 436/25125: Digestion or removing interfering materials
- Y10T 436/25375: Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- B01L: CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

Method of enriching specific cells from cellular samples are disclosed, comprising contacting in solution a cellular sample with affinity-tagged ligands (ATLs) each comprising a first ligand linked to an affinity tag, wherein the ligand selectively binds a cellular marker of the rare cells and the affinity tag can be selectively captured by a capture moiety, wherein the affinity tags do not comprise a magnetic particle; and flowing the sample through a microfluidic device comprising the capture moiety to selectively retain ATL-bound cells. Methods for enriching circulating tumor cells, and devices for enriching specific cells from cellular samples are also disclosed.

## Claims

### Claim 1

A method for enriching rare analytes from a sample comprising:
contacting in solution said sample with a plurality of affinity-tagged ligands (ATLs) wherein said mixture of ATL's comprises:
a first ATL comprising a first ligand that selectively binds a first marker of said rare analytes, wherein said first ligand is linked to a first affinity tag that is selectively captured by a first capture moiety; and
a second ATL comprising a second ligand that selectively binds a second marker of said rare analytes, wherein said second ligand is linked to a second affinity tag, wherein said second affinity tag is selectively captured by said first capture moiety; and
contacting said sample with said capture moiety to selectively enrich said rare analytes.

### Claim 2 (depends on 1)

The method of claim 1, wherein said first affinity tag and said second affinity tag are identical.

### Claim 3 (depends on 1)

The method of claim 1, wherein said mixture of ATL's comprises at least 3, 4, 5, 6, 7, 8, 9, or 10 ATL's each of which comprises an affinity tag that can be selectively captured by the first capture moiety.

### Claim 4 (depends on 1)

The method of claim 1, wherein said analytes are cells and said mixture is a blood sample.

### Claim 5 (depends on 1, 2)

The method of claim 1, 2, or 3 wherein each of said ATL's comprises a ratio of Ligand:Affinity Tag that is less than 1:5.

### Claim 6 (depends on 5)

The method of claim 5, wherein said capture moiety is in a microfluidic device.

### Claim 7 (depends on 6)

The method of claim 6, wherein said microfluidic device comprises an array of obstacles.

### Claim 8 (depends on 1, 2)

The method of claim 1, 2, or 3 wherein said affinity tag comprises biotin, desthiobiotin, histidine, polyhistidine, myc, hemagglutinin (HA), FLAG, fluorescence tag, tandem affinity purification (TAP) tags, FLAG, glutathione S transferase (GST) or derivatives thereof.

### Claim 9 (depends on 1, 2)

The method of claim 1, 2, or 3, wherein said ligand is linked to said affinity tag via a linker comprising one or more of modified dextran, polyethylene glycol, polypropylene glycol, polyvinyl alcohol, and polyvinylpyrrolidone.

### Claim 10 (depends on 1, 2)

The method of claim 1 or 2 wherein the cellular marker is a cancer marker for one or more of breast, prostate, liver, ovary, skin, colon, rectum, cervix, esophagus, stomach, brain, lung, or endometrium cancer.

### Claim 11 (depends on 1, 2)

The method of claim 1, 2, or 3, wherein the ligand selectively binds epidermal growth factor receptor (EGFR) or folic acid receptor.

### Claim 12 (depends on 1, 2)

The method of claim 1, 2, or 3, wherein the capture moiety comprises avidin, streptavidin, Neutravidin™, nickel, or glutathione.
